Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.68 |
| ▸ | LPL | P06858 | 8/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331631 | 0.87 | LIPG (0.63) | LIPGLPLF11NOS1 | |
| Hydrochloric Acid SCHEMBL1631610 | 0.85 | LIPG (0.61) | LIPGLPLF11NOS1 | |
| SCHEMBL30477495 | 0.85 | LIPG (0.80) | LIPGLPLF11 | |
| SCHEMBL23071684 | 0.85 | LIPG (0.70) | LIPGLPLF11 | |
| SCHEMBL12215735 | 0.85 | LIPG (0.80) | LIPGLPLF11 | |
| SCHEMBL4315178 | 0.84 | LIPG (0.68) | LIPGLPLF11 | |
| SCHEMBL29478527 | 0.84 | LIPG (0.68) | LIPGLPLF11 | |
| SCHEMBL25813029 | 0.84 | LIPG (0.68) | LIPGLPLF11 | |
| SCHEMBL14750160 | 0.83 | LIPG (0.91) | LIPGLPLF11 | |
| SCHEMBL24837499 | 0.83 | LIPG (0.67) | LIPGLPLF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018072697-A1 | OXADIAZOLE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, COMPOSITE, AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2018-04-26 | — | — | WO | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| EP-1966163-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | Boehringer Ingelheim International GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007076247-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076247-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | PRKCQ, PRKCZ, PRKAR2B | LIPG 2370/4885LPL 3856/4885TAAR1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.